All In Biotech

Investigational drug · Phase 3

HMPL-453

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor.

Phase 3

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

8

Any phase or sponsor naming "HMPL-453"

First trial start

2020

Sep 3, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HMPL-453", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Intrahepatic Cholangiocarcinoma
  • Solid Tumor, Adult
  • Solid Tumor

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "HMPL-453" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Intrahepatic Cholangiocarcinoma

  • Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials

    CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.